Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-23-278885
Filing Date
2023-11-16
Accepted
2023-11-16 16:45:05
Documents
10

Document Format Files

Seq Description Document Type Size
1 DEFM14A d873327ddefm14a.htm DEFM14A 2152388
2 GRAPHIC g873327g02m95.jpg GRAPHIC 75026
3 GRAPHIC g873327g06i56.jpg GRAPHIC 23376
4 GRAPHIC g873327g06i89.jpg GRAPHIC 447992
5 GRAPHIC g873327g07o89.jpg GRAPHIC 483098
6 GRAPHIC g873327g09a55.jpg GRAPHIC 434795
7 GRAPHIC g873327g10a52.jpg GRAPHIC 487088
8 GRAPHIC g873327g18p98.jpg GRAPHIC 48529
9 GRAPHIC g873327g55d76.jpg GRAPHIC 15915
10 GRAPHIC g873327g99f18.jpg GRAPHIC 15716
  Complete submission text file 0001193125-23-278885.txt   4952620
Mailing Address 245 HAMMERSMITH ROAD, 3RD FLOOR LONDON X0 W6 8PW
Business Address 245 HAMMERSMITH ROAD, 3RD FLOOR LONDON X0 W6 8PW 011-44-0-203-3846700
Orchard Therapeutics plc (Filer) CIK: 0001748907 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-38722 | Film No.: 231415220
SIC: 2836 Biological Products, (No Diagnostic Substances)